Our leaders combine over 85 years of experience in the healthcare and pharmaceutical industry.
Together our team launched the first vaginal pH modulator, a unique mechanism of action, to bring much-needed non-hormonal innovation to the contraceptive space with Phexxi® (lactic acid, citric acid and potassium bitartrate) vaginal gel.
In less than one year, and during a global pandemic, our leadership achieved dramatic growth in prescriptions, dispensed units and our prescriber base in a new contraception category that will disrupt and change the contraceptive space forever. This is only the beginning of the Evofem revolution.
Chief Executive Officer
Saundra Pelletier has served as Chief Executive Officer, President and Executive Director of Evofem Biosciences since February 2015. Ms. Pelletier has been responsible for the company’s growth and evolution, and she led Evofem’s transition to the public market in January 2018 (NASDAQ: EVFM).
Ms. Pelletier has assembled an impressive team of seasoned pharmaceutical professionals that have a deep understanding of the women’s healthcare market and what women want, and she attracted new investor capital. She has also led multiple equity financing rounds which have raised over $491 million.
Chief Financial Officer
Mr. File has served as Evofem Biosciences’ Chief Financial Officer since April 2015. Mr. File has approximately 25 years of diverse accounting and finance experience within a variety of both public and private biotechnology and biopharmaceutical companies.
Most recently, Mr. File provided executive financial and accounting oversight services to various biotechnology companies in San Diego, California, assisting in their initial public offering process and helping to establish and improve their accounting and finance operations as publicly-traded entities.
Chief Commercial Officer
Mr. Barrans has served as Evofem Biosciences’ Chief Commercial Officer since August 2016. Mr. Barrans has over 25 years in the women’s healthcare pharmaceuticals and biotechnology space. As the Chief Commercial Officer, he is responsible for the commercial launch and lifecycle management of the Evofem Biosciences product portfolio, oversees manufacturing and supply chain, and provides executive leadership to the sales and marketing team.
Prior to joining Evofem Biosciences, Mr. Barrans was the Senior Director of Women’s Healthcare Marketing for Teva Pharmaceuticals from 2012 to June 2015.
Executive Vice President,
General Counsel & Secretary
Mr. Fitzpatrick has served as the Executive Vice President, General Counsel and Secretary of Evofem Biosciences since October 2017. Mr. Fitzpatrick is responsible for our corporate governance, legal, corporate development, intellectual property and risk management functions.
Prior to joining Evofem, Mr. Fitzpatrick served as Chief Legal Officer of Kyriba Corporation from 2014 to 2015 and Senior Vice President, General Counsel, Compliance Officer and Secretary of Verenium Corporation, a publicly traded biotechnology company from 2010 to 2014.